Niacinamide (Nicotinamide) · Evidence-First Lite Reference
Niacinamide (Nicotinamide) Lite reference · evidence-first overview + FAQ. Educational only.
Overview
This is a Lite reference page for Niacinamide (Nicotinamide). For deep evidence (mechanism, dose-response, full PMID citations), please consult primary literature and the cross-linked references on related goal/lifestyle pages.
Tags
Body Systems: Skin & Connective Tissue · METABOLISM · Mitochondrial & Cellular Energy
Mechanisms: NAD+ salvage substrate · Topical skin barrier support
Evidence Tier: lite-tier-c-systemic-tier-a-topical
Layer: B (Lite reference)
Frequently Asked Questions
The questions below cover the most common questions on Niacinamide (Nicotinamide). This is an evidence-first Lite reference page; for deep mechanism narratives, dose-response analyses, and full PMID citations please consult primary literature. Answers below intentionally disclose evidence-base limitations rather than overstate the supplement category.
1. What is niacinamide?
Niacinamide, also called nicotinamide, is the amide form of vitamin B3. It can feed the NAD+ salvage pathway, but consumer NAD+ precursor claims should be separated from its better-established vitamin-B3 adequacy role and its topical dermatology evidence.
2. What is the strongest evidence anchor for niacinamide in this Lite page?
The topical skin anchor is Bissett 2005 (PMID 16029679), a 12-week study using 5% topical niacinamide for facial skin appearance endpoints. This supports skin-beauty context more directly than broad systemic NAD+ claims. See the skin-beauty goal page at /goals/skin-beauty/ for adjacent ingredient context.
3. Is oral niacinamide the same as niacin?
No. Niacinamide and niacin are both vitamin B3 forms, but niacinamide does not share the same acute flushing profile as nicotinic acid. High systemic intakes still require caution: sustained intake above approximately 3 g/day has been associated with hepatotoxicity (liver-safety concerns) in reported case series. The NIH-ODS Tolerable Upper Intake Level for total niacin from supplements is 35 mg/day for adults.
4. What dose frame is used here?
The public card separates RDA-level vitamin B3 adequacy from higher-dose NAD+ precursor use. It lists 14-18 mg/day for deficiency-prevention adequacy, 500-1500 mg/day as a Tier C NAD+ precursor frame, and 5% topical niacinamide for the Bissett 2005 skin study.
5. Where does this page sit in the evidence library?
This is a Lite reference page. For deeper evidence please consult primary literature on topical cosmetic studies (Bissett 2005 anchor), vitamin-B3 deficiency biology, authorized niacin-family claims, and high-dose systemic safety boundaries.